Abstract: The present invention relates to a method for inducing an immune response to the dengue virus, on the basis of DNA and 17D chimeric virus vaccines in combined or co-administered immunisation. The scope of the present invention also includes DNA vaccines against the four serotypes of the dengue virus, produced by forming, from each viral serotype of the dengue virus (DENV1-4), various recombinant plasmids that contain the gene that codes for the E protein, or that contain only the sequence that corresponds to the domain III of this protein. The invention also provides a vaccine composition consisting of (a) DNA vaccines against the four serotypes of the dengue virus; (b) chimeric viruses comprising the modified yellow fever vaccination virus 17D; and (c) a pharmaceutically acceptable carrier, all of which are covered by the scope of the invention.

Abstract: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of nucleotides encoding whole or part of heterologous proteins, through the following method: (a) modification of the heterologous nucleotides sequences in such way that when cloned and expressed in a vector virus, the 5? region nucleotides present in the 5? edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3? region, the correspondent genome region in the whole or part of the domains of the stem and anchor of the protein E of the vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mentioned vector virus; (b) insertion of the modified heterologous sequences in (a) in the intergenic region at the structural protein E level and of the nonstructural NS1 vector virus; (c) obtaining the non pathogenic recombinant virus with immunologic properties, having the heterologous sequences

Abstract: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, the present in the 5? region nucleotides present in the 5? edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3? region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of constructural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having the

Abstract: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, the present in the 5? region nucleotides present in the 5? edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3? region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of constructural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having the

Abstract: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way that when cloned and expressed in the vector virus, they present in the 5? region nucleotides present in the 5? edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3? region, the correspondent genome region in the whole or part of the spheres of the stem and anchor of the protein E of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of nonstructural NS1 vector virus; (c) obtaining the non-pathogenic recombinant virus and owner of the immunologic properties, having the he

Abstract: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, the present in the 5? region nucleotides present in the 5? edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3? region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of nonstructural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having the

Abstract: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, the present in the 5? region nucleotides present in the 5? edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3? region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of nonstructural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having the

Abstract: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, they present in the 5? region, nucleotides present in the 5? edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3? region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not compromising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of on structural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having

Abstract: The present invention relates to an attenuated, recombinant viral vaccine against yellow fever which expresses heterologous sequences of a lentivirus and is used as an immunisation agent to induce an immune response to lentivirus.

Abstract: The present invention relates to a method for inducing an immune response to the dengue virus, on the basis of DNA and 17D chimeric virus vaccines in combined or co-administered immunisation. The scope of the present invention also includes DNA vaccines against the four serotypes of the dengue virus, produced by forming, from each viral serotype of the dengue virus (DENV1-4), various recombinant plasmids that contain the gene that codes for the E protein, or that contain only the sequence that corresponds to the domain III of this protein. The invention also provides a vaccine composition consisting of (a) DNA vaccines against the four serotypes of the dengue virus; (b) chimeric viruses comprising the modified yellow fever vaccination virus 17D; and (c) a pharmaceutically acceptable carrier, all of which are covered by the scope of the invention.

Abstract: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, they present in the 5? region, nucleotides present in the 5? edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3? region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not compromising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of on structural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having

Abstract: The present invention relates to a vaccine against infections caused by flavivirus. More particularly to the use of the YF vaccine virus (17D) to express at the level of its envelope, protein epitopes from other pathogens which will elicit a specific immune response to the parental pathogen.

Abstract: The present invention relates to a vaccine against infections caused by flavivirus. More particularly to the use of the YF vaccine virus (17D) to express at the level of its envelope, protein epitopes from other pathogens which will elicit a specific immune response to the parental pathogen.

Abstract: The present invention is related to a vaccine composition for humans against YF infections consisting essencially of a recombinant YF virus, YFiv5.2/DD, which is regenerated from YF infectious cDNA. There is provided new plasmids, pYF 5′3′ IV/G1/2 and pYFM 5.2/T3/27, which together, have the complete sequence of said YF infectious cDNA. The method for producing recombinant YF virus and the Original, Primary and Secondary Seed Lots are other embodiments of the present invention.

Abstract: The present invention is related to a vaccine composition for humans against YF infections consisting essentially of a recombinant YF virus, YFiv5.2/DD, which is regenerated from YF infectious cDNA. There are provided new plasmids, pYF 5′3′ IV/G1/2 and pYFM 5.2/T3/27, which together, have the complete sequence of said YF infectious cDNA. The method for producing recombinant YF virus and the Original, Primary and Secondary Seed Lots are other embodiments of the present invention.